en · de · es
semaglutide-notes.peptides4088.com › Data › Background And Molecular Profile — Reference Sheet

Background And Molecular Profile — Reference Sheet

By Editorial Desk · published 2025-07-16 · last reviewed 2025-07-30 · Data

Adsorption is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-07-30. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Molecular Profile

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.

The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.

Handling, Storage, And Analytical Checks

Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.

Semaglutide at a glance

PropertyValueNotes
Molecular formula (free base)C187H291N45O59Approximate; salt and hydrate forms differ
Molecular weight~4113.6 DaVaries with counterion and hydration
AppearanceWhite to off-white powderLyophilized research material
Solubility classFreely soluble in waterAs formulated; native peptide less stable near neutral pH
Typical storage2 to 8 degrees CelsiusProtect from light; avoid repeated freeze-thaw

Handling, Storage, and Analytical Verification

Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.

Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.

Related pages on this site

Handling, Storage, and Characterization

Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.

Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.

Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.

结构特征与受体作用机制

皮下注射后吸收相对缓慢,绝对生物利用度约为百分之八十九,血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢,终末半衰期约为一百六十五小时,接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升,血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主,相关产物主要经尿液与粪便排出。

序列层面的改动同时解决了两个问题,即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟,主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库,使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发,属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物,其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代,使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸,进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链,该侧链赋予分子与血浆白蛋白结合的能力。

Background and Drug Class

Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.

Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.

Background from the literature

=== Other formulations === The original oral formulation of selegiline was developed for the treatment of depression. However, it ended up being developed and approved for the treatment of Parkinson's disease instead. In any case, oral selegiline has been widely used off-label to treat depression. The transdermal patch form of selegiline was developed and approved specifically for the treatment of depression. It was also under development for the treatment of Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), cognition disorders, and Parkinson's disease, but development for these indications was discontinued. The ODT form of selegiline was developed and licensed exclusively for the treatment of Parkinson's disease.

=== Magnetic confinement fusion === In fusion devices, such as tokamaks and stellarators, ICRH antennas are installed in the machine vessel to heat the plasma using radio waves with frequencies in the range of the ion cyclotron resonance. ICRH provides localized heating of ions in fusion plasmas, which can generate a large population of energetic particles typically inaccessible with other heating methods (such as electron cyclotron resonance heating or neutral beam injection). The confinement properties of fast ions in plasma is a major research topic in fusion plasma physics.

Jurewizc further argues that the rest of the twelve nidanas show similarities with the terms and ideas found in Vedic cosmogeny, especially as it relates to the sacrificial fire (as a metaphor for desire and existence). These Vedic terms may have been adopted by the Buddha to communicate his message of not-self because his audience (often educated in Vedic thought) would understand their basic meaning. According to Jurewizc, dependent origination replicates the general Vedic creation model, but negates its metaphysics and its morals. Furthermore, Jurewizc argues that:This deprives the Vedic cosmogony of its positive meaning as the successful activity of the Absolute and presents it as a chain of absurd, meaningless changes which could only result in the repeated death of anyone who would reproduce this cosmogonic process in ritual activity and everyday life.According to Gombrich, the Buddhist tradition soon lost sight of their connection with the Vedic worldview that the Buddha was critiquing in the first four links of dependent origination. Though it was aware that at the fourth link there should be an appearance of an individual person, the Buddhist tradition equated rupa with the first skandha, and nama with the other four skandhas. Yet, as Gombrich notes, samkhara, vijnana, and vedana also appear as separate links in the twelvefold list, so this equation can't be correct for this nidana.

===== Cross-presentation ===== When HSPs are extracellular, they can bind to specific receptors on dendritic cells (DC) and promote cross-presentation of their carried peptides. The most important receptors in this case are scavenger receptors, mainly SRECI and LOX-1. CD91 scavenger receptor has been previously proposed as the common HSP receptor. But now its relevance is controversial because the majority of DC types does not express CD91 in relevant amounts and the binding capacity for many HSPs has not been proved. Stimulation of some scavenger receptors can even result in immunosuppression, this is the case for SRA. LOX-1 and SRECI when stimulated guide HSPs with their associated peptides into cross-presentation. LOX-1 binds mainly hsp60 and hsp70. SRECI is now considered to by the common heat-shock protein receptor because it binds hsp60, hsp70, hsp90, hsp110, gp96 and GRP170. The relevance for this type of cross-presentation is high especially in tumour-immunosurveillance. Thanks to the HSP, the bound peptide is protected against degradation in dendritic cell compartments and the efficiency of cross-presentation is higher. Also internalisation of HSP-peptide complex is more efficient than internalisation of soluble antigens. Tumor cells usually express only a few neo-antigens, which can be targeted by immune system and also not all tumor cells express them. Because of that the amount of tumor antigens is restricted and high efficiency of cross-presentation is necessary for mounting strong immune response.

Sources: en.wikipedia.org

Reference notes

Ukrainian authorities said they shot down 17 missiles and 31 drones launched from Russia overnight. Strikes were reported in Dnipro and Kharkiv, including an oil depot. In Kyiv, fragments of intercepted drones fell on the roof of a shopping centre, while a house and several cars were damaged. A Russian S-300 missile hit a dam in Karlivka, Donetsk Oblast, placing nearby settlements under threat of severe flooding from the Karlivske Reservoir. Two people were killed and 23 injured in a missile strike at a clinic in Dnipro. The Russian Defence Ministry claimed it had struck ammunition depots in those attacks and said all targets had been hit. In Russia, a blast alleged to have been caused by two Ukrainian drones damaged a residential and office building in Krasnodar. Four districts in Belgorod Oblast were shelled from the Ukrainian border, while a Ukrainian missile was reportedly shot down over Morozovsk, in Rostov Oblast. The United States announced sanctions against Ivan Maslov, head of the Wagner Group's operations in Mali, saying that the group was procuring weaponry across Africa to use in the war in Ukraine. The Japanese Foreign Ministry announced additional sanctions on Russia, saying that it would freeze the assets of 78 groups and 17 individuals, including army officers and ban exports to 80 entities such as military-affiliated research labs. It also said it would ban providing construction and engineering services to Russia.

==== Three-dimensional structure ==== The three-dimensional structure of heparin is complicated because iduronic acid may be present in either of two low-energy conformations when internally positioned within an oligosaccharide. The conformational equilibrium is influenced by the sulfation state of adjacent glucosamine sugars. Nevertheless, the solution structure of a heparin dodecasaccharide composed solely of six GlcNS(6S)-IdoA(2S) repeat units has been determined using a combination of NMR spectroscopy and molecular modeling techniques. Two models were constructed, one in which all IdoA(2S) were in the 2S0 conformation (A and B below), and one in which they are in the 1C4 conformation (C and D below). However, no evidence suggests that changes between these conformations occur in a concerted fashion. These models correspond to the protein data bank code 1HPN.

== Secondary structure == Because their backbones are longer than those of normal peptides, β-peptides form disparate secondary structures. The alkyl substituents at both the α and β positions in a β-amino acid favor a gauche conformation about the bond between the α-carbon and β-carbon. This also affects the thermodynamic stability of the structure. Many types of helix structures consisting of β-peptides have been reported. These conformation types are distinguished by the number of atoms in the hydrogen-bonded ring that is formed in solution; 8-helix, 10-helix, 12-helix, 14-helix, and 10/12-helix have been reported. Generally speaking, β-peptides form a more stable helix than α-peptides.

Sources: en.wikipedia.org

Frequently asked questions

What is the relationship between semaglutide and native GLP-1?

It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.

Does the oral form work the same way as the injectable form?

Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.

Is the peptide naturally present in the human body?

No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.

Should solutions be filtered before analysis?

Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.

Network